Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising - Tabular View

Tracking Information

First Received Date ^ICMJE

August 10, 2006

Last Updated Date

November 19, 2009

Start Date ^ICMJE

August 2006

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Days to resolution of ecchymoses, as determined by patient report and two double-blinded dermatologist raters who are asked to evaluate the appearance of the ecchymoses from digital photographs using a visual analog scale.

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00363038 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising

Official Title ^ICMJE

Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising

Brief Summary

The primary objective of this study is to determine the efficacy of different topical ointments compared with placebo for the resolution of post-laser induced bruising.

Detailed Description

The primary purpose of this study is to determine the efficacy of different topical ointments compared with placebo for the resolution of post-laser induced bruising.

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment

Condition ^ICMJE

Ecchymosis

Intervention ^ICMJE

Drug: Vitamin K
Drug: Vitamin K and Retinol
Drug: Arnica

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

July 2007

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Age 20-60
Subjects are in good health.
Subjects have willingness and the ability to understand and provide informed consent for participation in the study.

Exclusion Criteria:

Subjects who are currently using any anticoagulation therapy (Warfarin, Heparin, Aspirin)
Subjects who have a history of bleeding disorders.
Subjects who are unable to understand the protocol or to give informed consent
Subjects with mental illness
Subjects who are pregnant or nursing.
Subjects who have active systemic or local infection
Subjects with systemic or local skin disease.
Subjects with systemic illness.

Gender

Both

Ages

20 Years to 60 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00363038

Responsible Party

Study ID Numbers ^ICMJE

1253-015

Study Sponsor ^ICMJE

Northwestern University

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Murad Alam, MD

Northwestern University

Information Provided By

Northwestern University

Verification Date

November 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP